<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Terraf P</submitter><funding>NCI NIH HHS</funding><pagination>a006089</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8327883</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(4)</volume><pubmed_abstract>Comprehensive characterization of somatic genomic alterations has led to fundamental shifts in our understanding of tumor biology. In clinical practice, these studies can lead to modifications of diagnosis and/or specific treatment implications, fulfilling the promise of personalized medicine. Herein, we describe a 78-yr-old woman under surveillance for long-standing untreated chronic lymphocytic leukemia (CLL). Molecular studies from a peripheral blood specimen revealed a &lt;i>TP53&lt;/i> p.V157F mutation, whereas karyotype and fluorescence in situ hybridization (FISH) identified a 17p deletion, trisomy 12, and no evidence of &lt;i>IGH-CCND1&lt;/i> rearrangement. Positron emission tomography-computed tomography scan identified multistation intra-abdominal lymphadenopathy and a pulmonary nodule, and </pubmed_abstract><journal>Cold Spring Harbor molecular case studies</journal><pubmed_title>Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.</pubmed_title><pmcid>PMC8327883</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><pubmed_authors>Sholl LM</pubmed_authors><pubmed_authors>Terraf P</pubmed_authors><pubmed_authors>MacConaill LE</pubmed_authors><pubmed_authors>Kim A</pubmed_authors><pubmed_authors>Lindeman NI</pubmed_authors><pubmed_authors>Hwang DH</pubmed_authors><pubmed_authors>Davids MS</pubmed_authors><pubmed_authors>Stachler M</pubmed_authors><pubmed_authors>Dal Cin P</pubmed_authors><pubmed_authors>Awad MM</pubmed_authors><pubmed_authors>Garcia EP</pubmed_authors><pubmed_authors>Dubuc AM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.</name><description>Comprehensive characterization of somatic genomic alterations has led to fundamental shifts in our understanding of tumor biology. In clinical practice, these studies can lead to modifications of diagnosis and/or specific treatment implications, fulfilling the promise of personalized medicine. Herein, we describe a 78-yr-old woman under surveillance for long-standing untreated chronic lymphocytic leukemia (CLL). Molecular studies from a peripheral blood specimen revealed a &lt;i>TP53&lt;/i> p.V157F mutation, whereas karyotype and fluorescence in situ hybridization (FISH) identified a 17p deletion, trisomy 12, and no evidence of &lt;i>IGH-CCND1&lt;/i> rearrangement. Positron emission tomography-computed tomography scan identified multistation intra-abdominal lymphadenopathy and a pulmonary nodule, and </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2026-03-15T11:15:48.976Z</modification><creation>2025-06-01T01:33:11.271Z</creation></dates><accession>S-EPMC8327883</accession><cross_references><pubmed>34074652</pubmed><doi>10.1101/mcs.a006089</doi></cross_references></HashMap>